Vaccines, Blood & Biologics
Proper Name: Alpha-1-Proteinase Inhibitor (Human)
Manufacturer: Baxter Healthcare Corp, License #014
- For augmentation therapy in patients having congenital deficiency of alpha-1-proteinase inhibitor with clinically evident emphysema.
September 22, 2005 (Corrected Approval Letter)[ARCHIVED]
STN 125039/69, Fr.IV1 4 paste as an alternate starting material for the manufacture of ARALAST, as amended
March 21, 2003 Corrected Approval Letter - Aralast[ARCHIVED]
STN 125039/0, indicated for augmentation therapy in patients having congenital deficiency of alpha-1-proteinase inhibitor with clinically evident emphysema.
Summary Basis of Approval - Aralast Appendix to Summary Basis of Approval - Aralast
FDA Online Label Repository
Search this database for drug labeling and other information. The content has not been altered or verified by the FDA and may not be the labeling on currently distributed products or identical to the labeling that is approved.
Division of Communication and Consumer Affairs
Office of Communication, Outreach and Development
Food and Drug Administration
10903 New Hampshire Avenue
Building 71 Room 3103Silver Spring, MD 20993-0002